| Patents for A61K 38 - Medicinal preparations containing peptides (316,240) |
|---|
| 07/31/2008 | CA2676387A1 Combination therapy |
| 07/31/2008 | CA2676244A1 Use of anti-egfr antibodies in treatment of egfr mutant mediated disease |
| 07/31/2008 | CA2676143A1 Modification of exosomal components for use as a vaccine |
| 07/31/2008 | CA2676105A1 The tetracyclic anthraquinones possessing anti-cancer effect |
| 07/31/2008 | CA2676098A1 Soluble fcgammaria and related methods |
| 07/31/2008 | CA2675764A1 Treating hepatitis c virus infection |
| 07/31/2008 | CA2674908A1 Tri-demethylation-capable protein complex, method of its preparation and its use |
| 07/31/2008 | CA2674384A1 A peptide composition and a method of promoting cartilage formation |
| 07/31/2008 | CA2674213A1 Purification of fc-taci fusion proteins using the oilbody technology |
| 07/31/2008 | CA2674021A1 Method for assaying antibodies in body fluids by immune reaction with glycoprotein 2 (gp2) from zymogenic granules of the pancreas for the differential diagnosis of inflammatory intestinal diseases and chronic pancreatitis |
| 07/31/2008 | CA2642273A1 Bifunctional histone deacetylase inhibitors |
| 07/30/2008 | EP1950307A1 Gene transfer into airway epithelial stem cell by using lentiviral vector pseudotyped with rna virus or dna virus spike protein |
| 07/30/2008 | EP1950302A2 Streptococcus antigens |
| 07/30/2008 | EP1950301A2 Antibody for use in Therapy |
| 07/30/2008 | EP1950300A2 Antibody variants with higher binding affinity compared to parent antibodies |
| 07/30/2008 | EP1950299A1 Mammalian receptor proteins; related reagents and methods |
| 07/30/2008 | EP1950298A2 Hemoglobin mutants with increased soluble expression and/or reduced nitric oxide scavenging |
| 07/30/2008 | EP1950297A2 Compositions and methods for treating neoplastic disease using chemotherapy and radiation sensitizers |
| 07/30/2008 | EP1950286A1 Tri-demethylation-capable protein complex, method of its preparation and its use |
| 07/30/2008 | EP1950226A2 Receptors for human interleukin-12 |
| 07/30/2008 | EP1950224A2 Pharmacologically active peptide conjugates having a reduced tendency towards enzymatic hydrolysis |
| 07/30/2008 | EP1950223A2 Pharmacologically active peptide conjugates having a reduced tendency towards enzymatic hydrolysis |
| 07/30/2008 | EP1950222A1 Method for proving antibodies in body fluids via an immune reaction with glycoprotein 2 (GP2) from zymogen granula of the pancreas for a differential diagnosis of inflammable intestinal illnesses and chronic pancreatitis |
| 07/30/2008 | EP1949936A2 Controlled release composition and method of producing the same |
| 07/30/2008 | EP1949915A2 Method and system to remove soluble TNFR1, TNFR2, and IL2 in patients |
| 07/30/2008 | EP1949914A1 Prevention and treatment of autoimmune disease with luminally administered polyclonal antibodies |
| 07/30/2008 | EP1949912A2 Treatment of chronic lymphcytic leukemia (CLL) using chimeric anti-CD20 antibody |
| 07/30/2008 | EP1949911A2 Treatment of chronique lymphocytic leukemia using chimeric anti-CD20 antibody. |
| 07/30/2008 | EP1949910A1 Treatment of chronic lymphocytic leukemia (CLL) using chimeric anti-CD20 antibody. |
| 07/30/2008 | EP1949909A1 Use of Botulinum Toxin Therapy for Treatment of Urge Type Dysfunction |
| 07/30/2008 | EP1949908A1 Combined use of derivatives of GLP-1 analogs and PPAR ligands |
| 07/30/2008 | EP1949907A1 Novel application of heparin-binding epidermal growth factor-like growth factor for medical purposes |
| 07/30/2008 | EP1949906A1 Agent for correcting stress-inducing neuro-mediator, neuro- endocrine and metabolic disturbances and method for preventing and treating concomitant pathological conditions |
| 07/30/2008 | EP1949890A2 Implantable gel compositions and method of manufacture |
| 07/30/2008 | EP1948793A2 Method for conversion of uric acid to allantoin and related enzymes |
| 07/30/2008 | EP1948690A2 Compositions and methods for modulating hemostasis |
| 07/30/2008 | EP1948689A1 High activity growth factor mutants |
| 07/30/2008 | EP1948688A2 Compositions of and methods of using stabilized psma dimers |
| 07/30/2008 | EP1948686A2 C-reactive protein and its use to treat systemic lupus erythematosus and related conditions |
| 07/30/2008 | EP1948680A2 Methods and compounds for lymphoma cell detection and isolation |
| 07/30/2008 | EP1948678A1 Compounds for enzyme inhibition |
| 07/30/2008 | EP1948246A2 Stem cell factor therapy for tissue injury |
| 07/30/2008 | EP1948225A1 Use of liposomes in a carrier comprising a continuous hydrophobic phase as a vehicle for cancer treatment |
| 07/30/2008 | EP1948224A1 Stable formulation of amorphous perindopril salts, a process for their preparation, especially industrial preparation, and their use in the therapy of hypertension |
| 07/30/2008 | EP1948223A1 Sumoylation control agent and uses thereof |
| 07/30/2008 | EP1948222A1 Method for treating disease or disorder of adult central nervous system associated with tissue shrinkage or atrophy by administration of insulin |
| 07/30/2008 | EP1948221A2 Human growth hormone patch formulations |
| 07/30/2008 | EP1948220A2 Methods of decreasing vascular calcification using il-1 inhibitors |
| 07/30/2008 | EP1948219A2 Vegf analogs and methods of use |
| 07/30/2008 | EP1948218A2 Osteogenic device for inducing bone formation in clinical contexts |
| 07/30/2008 | EP1948217A2 Use of nerve growth factor in eye-drops for therapy of pathologies of the central nervous system, such as alzheimer's and parkinson's disease |
| 07/30/2008 | EP1948216A2 Method of treating acute failure with thrombomodulin variant |
| 07/30/2008 | EP1948215A1 Inhibitors of parp activity and uses thereof |
| 07/30/2008 | EP1948214A2 Tnf-alpha blocker treatment for enterocolitis associated with immunostimulatory therapeutic antibody therapy |
| 07/30/2008 | EP1948213A2 Methods to predict and prevent resistance to taxoid compounds |
| 07/30/2008 | EP1948212A2 Treatment of dry eye |
| 07/30/2008 | EP1948211A2 Modulators of nod1 signaling |
| 07/30/2008 | EP1948210A1 Method of treatment for ischemic heart disease |
| 07/30/2008 | EP1948199A1 Pharmaceutical compositions for the administration of aptamers |
| 07/30/2008 | EP1948171A1 New method for treating cancer based on the modulation of calcineurin |
| 07/30/2008 | EP1948157A2 Compositions for treating dermatological and neurological disorders |
| 07/30/2008 | EP1670495B1 Stabilization of pharmaceutical epo formulations with small peptides |
| 07/30/2008 | EP1651665B1 Method for the purification of a non-immunoglobulin protein comprising an immunoglobulin-like (ig-like) domain |
| 07/30/2008 | EP1648924B1 Dipeptide transglutaminase inhibitors and methods of using the same |
| 07/30/2008 | EP1549673B1 Novel mhc ii associated peptides |
| 07/30/2008 | EP1480646B1 Anti-infective agents and/or immunomodulators used for preventive therapy following an acute cerebrovascular accident |
| 07/30/2008 | EP1478394B1 Stabilized TNFR-Fc composition comprising arginine |
| 07/30/2008 | EP1478331A4 Method of stimulation of melanin production and induction of skin tanning |
| 07/30/2008 | EP1465995B1 Bispecific antisense olignucleotides that inhibit igfbp-2 and igfbp-5 and methods of using same |
| 07/30/2008 | EP1401259B1 Delta-4 desaturase genes and uses thereof |
| 07/30/2008 | EP1366078B1 Ige receptor antagonists |
| 07/30/2008 | EP1363654B1 Fab i and inhibition of apicomplexan parasites |
| 07/30/2008 | EP1355920B1 Extractive purification of lipopeptide antibiotics |
| 07/30/2008 | EP1289567B1 Lyophilizable and enhanced compacted nucleic acids |
| 07/30/2008 | EP1285663B1 Protective interferon-beta against reinfection after liver transplantation |
| 07/30/2008 | EP1276759B1 Reductive alkylation process on glycopeptides |
| 07/30/2008 | EP1239876B1 Hcv vaccine compositions |
| 07/30/2008 | EP1226170B1 Human chordin and polynucleotides encoding the same |
| 07/30/2008 | EP1159438B1 Use of adenoviral vector for synovial cell transduction |
| 07/30/2008 | EP1144600B1 Akt-3 nucleic acids, polypeptides, and uses thereof |
| 07/30/2008 | EP1076065B1 Polypeptide having antihuman immunodeficiency virus activity, gene encoding the polypeptide and process for producing the polypeptide |
| 07/30/2008 | EP1025124B1 Low-toxicity human interferon-alpha analogues |
| 07/30/2008 | EP0994728B1 Recombinant antibodies specific for beta-amyloid ends, dna encoding and methods of use thereof |
| 07/30/2008 | EP0912738B1 Antigen binding fragments that specifically detect cancer cells, nucleotides encoding the fragments, and use thereof for the prophylaxis and detection of cancers |
| 07/30/2008 | EP0776209B1 Polynucleic acids and proteins from a porcine reproductive and respiratory syndrome virus and uses thereof |
| 07/30/2008 | CN101233231A Anti-obesity agent and anti-obesity food |
| 07/30/2008 | CN101233229A Processes for the manufacture of sterilized pancreatin powder |
| 07/30/2008 | CN101233151A Tight junction modulating peptide components for enhancing mucosal delivery of therapeutic agents |
| 07/30/2008 | CN101233148A Macrocyclic peptides as HCV NS3 protease inhibitors |
| 07/30/2008 | CN101233146A Inhibitors of cancer cell, t-cell and keratinocyte proliferation |
| 07/30/2008 | CN101233137A Macrocylic inhibitors of hepatitis c virus |
| 07/30/2008 | CN101232903A Toxin peptides with extended blood halflife |
| 07/30/2008 | CN101232900A Use of the ides proteinase (from s. pyogenes) for treating autoimmune diseases and graft rejection |
| 07/30/2008 | CN101232899A Method of preserving the function of insulin-producing cells |
| 07/30/2008 | CN101232898A Use of VEGF for wound healing |
| 07/30/2008 | CN101232897A Angiogenetic agent containing adrenomedulin as the active ingredient |
| 07/30/2008 | CN101232896A Method of treating or preventing tissue deterioration, injury or damage due to congestive heart failure |
| 07/30/2008 | CN101232895A Therapeutic peptides for the treatment of metastatic cancer |
| 07/30/2008 | CN101232894A Anticancer agent to be combined with telomelysin |
| 07/30/2008 | CN101232874A Apparatus and method for transdermal delivery of natriuretic peptides |